Alphabet-owned Verily has launched the Project Baseline Study, a collaborative effort with Stanford Medicine and Duke University School of Medicine to amass a large collection of broad phenotypic health data in hopes of developing a well-defined reference of human health.
Project Baseline aims to gather data from around 10,000 participants, each of whom will be followed for four years, and will...
Verily has debuted a new health-tracking wearable designed for use in a series of observational and longitudinal studies. With the aptly dubbed Study Watch – which is not available for consumer purchase – the Alphabet subsidiary formerly known as Google Life Sciences aims to push new boundaries in the size, scope and sophistication of wearable data-gathering.
Featuring numerous physiological and...
Google Life Sciences has finally gotten its new name as an independent company under the aegis of Alphabet: Verily. With the launch of a new website, the company has also clarified and cemented its mission: to bring different healthcare and technology stakeholders together to reinvent areas of healthcare.
"Imagine a chemist and an engineer and a doctor and a behavioral scientist, all working...
Google subsidiary Alphabet, has hired Dr. Tom Insel, former director of the National Institute of Mental Health (NIMH), to spearhead the company's mental health efforts in its life sciences division. Insel has worked as director of NIMH for 13 years before he moved to Google. In a statement about his transition, Insel said, "The GLS mission is about creating technology that can help with earlier...
An Oscar-branded Misfit Flash device.
Oscar, a small New York City-based health insurer noted for its individual focus and digital health savvy, has secured a $32.5 million investment from Google Capital, one of the search giant's two investment arms. The investment may well be strategic, according to the Wall Street Journal, which broke the story.
Last April, Oscar raised $145 million in a...
Google and Novartis are working on two smart contact lenses, and news broke this week about both of them: A new patent application sheds light on how Google might power its glucose-sensing contact lens, just a week after partner Novartis told a Swiss newspaper it was on track for human trials in 2016 of an autofocus lens for presbyopia patients.
Patent applications don't always presage exactly...
The old Dexcom Share, with charging cradle.
DexCom has partnered with Google Life Sciences to develop the next generation of DexCom's CGM -- a device that is "the size of a dime", less expensive than current CGMs, and that the companies hope will eventually replace the fingerstick glucometer. The device is not just for people with Type 1 diabetes but also for those with Type 2 diabetes.
"Our...
